3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
53
Carcinoma, Non-Small-Cell Lung
50
Carcinoma, Renal Cell
32
Neoplasms
29
Neoplasm Metastasis
24
Colorectal Neoplasms
21
Carcinoma, Hepatocellular
21
Squamous Cell Carcinoma of Head and Neck
18
Stomach Neoplasms
16
Triple Negative Breast Neoplasms
15
Ovarian Neoplasms
14
Small Cell Lung Carcinoma
11
Pancreatic Neoplasms
11
Lung Neoplasms
11
Hodgkin Disease
11
Carcinoma, Transitional Cell
10
Advanced Cancer
9
Sarcoma
8
Recurrence
8
Head and Neck Neoplasms
8
Solid Tumor
7
Prostatic Neoplasms
7
Lymphoma, Non-Hodgkin
7
Endometrial Neoplasms
7
Uterine Cervical Neoplasms
6
Urinary Bladder Neoplasms
6
Carcinoma, Merkel Cell
6
Breast Neoplasms
6
Mesothelioma
5
Glioblastoma
5
Interventions
Cyclophosphamide
5
Brentuximab Vedotin
5
Vincristine
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Ifosfamide
4
Etoposide
4
Doxorubicin
4
Carboplatin
4
romidepsin
3
fludarabine phosphate
3
brigatinib
3
Prednisone
3
Lenalidomide
3
Everolimus
3
10-propargyl-10-deazaaminopterin
3
pembrolizumab
2
indolepropanol phosphate
2
Whole-Body Irradiation
2
Vorinostat
2
Mycophenolic Acid
2
Microarray Analysis
2
Immunohistochemistry
2
Gene Expression Profiling
2
Cytarabine
2
Cyclosporine
2
Clofarabine
2
Bendamustine Hydrochloride
2
veliparib
1
repotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Large-Cell, Anaplastic
×
Nivolumab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled